Dieci MV - Search Results

1

Quantification of residual risk of relapse in breast cancer patients optimally treated.

Dieci MV, Arnedos M, Delaloge S, Andre F. Dieci MV, et al. Breast. 2013 Aug;22 Suppl 2:S92-5. doi: 10.1016/j.breast.2013.07.017. Breast. 2013. PMID: 24074801 Free article. Review.

2

Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer.

Andre F, Dieci MV, Dubsky P, Sotiriou C, Curigliano G, Denkert C, Loi S. Andre F, et al. Among authors: dieci mv. Clin Cancer Res. 2013 Jan 1;19(1):28-33. doi: 10.1158/1078-0432.CCR-11-2701. Epub 2012 Dec 20. Clin Cancer Res. 2013. PMID: 23258741 Review.

3

Landscape and evolution of therapeutic research for breast cancer patients.

Dogan S, Dieci MV, Goubar A, Arnedos M, Delaloge S, Andre F. Dogan S, et al. Among authors: dieci mv. Breast Cancer Res Treat. 2013 Feb;138(1):319-24. doi: 10.1007/s10549-013-2436-y. Epub 2013 Feb 14. Breast Cancer Res Treat. 2013. PMID: 23408207

4

Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives.

Dieci MV, Arnedos M, Andre F, Soria JC. Dieci MV, et al. Cancer Discov. 2013 Mar;3(3):264-79. doi: 10.1158/2159-8290.CD-12-0362. Epub 2013 Feb 15. Cancer Discov. 2013. PMID: 23418312 Review.

5

Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers.

Alsafadi S, Even C, Falet C, Goubar A, Commo F, Scott V, Quidville V, Albiges L, Dieci MV, Guegan J, Lazar V, Ahomadegbe JC, Delaloge S, André F. Alsafadi S, et al. Among authors: dieci mv. Clin Breast Cancer. 2013 Oct;13(5):401-8. doi: 10.1016/j.clbc.2013.02.001. Epub 2013 Jul 3. Clin Breast Cancer. 2013. PMID: 23830798

6

New strategies to overcome resistance to mammalian target of rapamycin inhibitors in breast cancer.

Vicier C, Dieci MV, Andre F. Vicier C, et al. Among authors: dieci mv. Curr Opin Oncol. 2013 Nov;25(6):587-93. doi: 10.1097/CCO.0000000000000014. Curr Opin Oncol. 2013. PMID: 24097108 Review.

7

Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study.

Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, Ficarra G, Mathieu MC, Delaloge S, Curigliano G, Andre F. Dieci MV, et al. Ann Oncol. 2014 Mar;25(3):611-618. doi: 10.1093/annonc/mdt556. Epub 2014 Jan 8. Ann Oncol. 2014. PMID: 24401929 Free PMC article.

8

Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact.

Dieci MV, Piacentini F, Dominici M, Omarini C, Goubar A, Ficarra G, Conte P, Guarneri V. Dieci MV, et al. Anticancer Res. 2014 Jul;34(7):3657-62. Anticancer Res. 2014. PMID: 24982383

9

Clinical development of mTOR inhibitors in breast cancer.

Vicier C, Dieci MV, Arnedos M, Delaloge S, Viens P, Andre F. Vicier C, et al. Among authors: dieci mv. Breast Cancer Res. 2014 Feb 17;16(1):203. doi: 10.1186/bcr3618. Breast Cancer Res. 2014. PMID: 25189767 Free PMC article. Review.

10

Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.

Dieci MV, Mathieu MC, Guarneri V, Conte P, Delaloge S, Andre F, Goubar A. Dieci MV, et al. Ann Oncol. 2015 Aug;26(8):1698-704. doi: 10.1093/annonc/mdv239. Epub 2015 May 20. Ann Oncol. 2015. PMID: 25995301 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

177 results

Search Page

Filters